13F-HR filed by Flagship Pioneering, LLC
Flagship Pioneering, LLC filed this 13F-HR for the quarter ended 2022-09-30, filed 2022-11-14, with 12 holding rows worth $2,375,805,000.
- Accession
- 0000950123-22-012261
- Filer
- CIK 1400240
- Filed
- 2022-11-14
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2022
A holdings report, 35 entries on the cover page, a total value of $2,375,805,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $2,375,805,000 with VALUE read as thousands by filing date, 13F file number 028-17559. The quarter's positions are built on this report. The resolved quarter.
Other managers
- included managerFlagship Ventures Fund V General Partner LLC 028-18466
- included managerFlagship Ventures Fund IV General Partner LLC 028-17238
- included managerNoubar Afeyan 028-19988
- included managerFlagship Opportunities Fund I General Partner LLC 028-20999
- included managerFlagship Pioneering Special Opportunities Fund II General Partner LLC 028-20997
- included managerNutritional Health Fund LTP General Partner LLC 028-21001
- included managerFlagship Pioneering Fund VI General Partner LLC 028-20998
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| MODERNA INC | 60770K107 | COM | 12,886,743 | $1,523,857,000 | thousands by filing date | |
| SANA BIOTECHNOLOGY INC | 799566104 | COM | 34,239,018 | $205,434,000 | thousands by filing date | |
| SERES THERAPEUTICS INC | 81750R102 | COM | 23,117,045 | $148,411,000 | thousands by filing date | |
| OMEGA THERAPEUTICS INC | 68217N105 | COMMON STOCK | 25,902,269 | $140,391,000 | thousands by filing date | |
| FOGHORN THERAPEUTICS INC | 344174107 | COMMON STOCK | 12,674,120 | $108,744,000 | thousands by filing date | |
| EVELO BIOSCIENCES INC | 299734103 | COM | 50,427,328 | $105,393,000 | thousands by filing date | |
| DENALI THERAPEUTICS INC COM | 24823R105 | Stock | 2,619,968 | $80,407,000 | thousands by filing date | |
| AXCELLA HEALTH INC | 05454B105 | COM | 18,867,785 | $32,264,000 | thousands by filing date | |
| RUBIUS THERAPEUTICS INC | 78116T103 | COM | 38,506,526 | $16,557,000 | thousands by filing date | |
| SYROS PHARMACEUTICALS INC | 87184Q206 | COM NEW | 993,848 | $6,400,000 | thousands by filing date | |
| SIGILON THERAPEUTICS INC | 82657L107 | COM | 10,370,369 | $5,185,000 | thousands by filing date | |
| CODIAK BIOSCIENCES INC | 192010106 | COM | 3,540,636 | $2,762,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-22-012261 | this filing | 2022-11-14 | acceptance time not in the bulk data set |